We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
Read MoreHide Full Article
Key Takeaways
NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients.
Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform.
NVCR's Optune Lua uses alternating electric fields to disrupt cancer cell division in NSCLC.
Novocure (NVCR - Free Report) recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program.
In Japan, Optune Lua is indicated for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable, advanced or recurrent Non???Small Cell Lung Cancer (NSCLC) who have experienced disease progression following platinum-based chemotherapy.
Per management, lung cancer continues to be a major contributor to cancer-related mortality in Japan, underscoring the pressing need for broader access to approved treatment options. The decision by Japan’s Ministry of Health, Labour and Welfare to include Optune Lua under the country’s National Health Insurance reimbursement framework enables patients with advanced Non-Small Cell Lung Cancer to access Optune Lua as an additional therapeutic option.
Likely Trend of NVCR Stock Following the News
Shares of NVCR have lost 3.5% since the announcement on March 2. Over the past six months, shares of the company gained 3% compared with the industry’s 15.5% growth and the S&P 500’s 4.5% rise.
In the long run, the reimbursement approval for Optune Lua in Japan is expected to strengthen the growth prospects of Novocure by expanding patient access through the country’s National Health Insurance. Coverage in Japan, one of the world’s largest healthcare markets, could support increased adoption of the therapy among patients with NSCLC. National insurance coverage reduces financial barriers for patients and healthcare providers, which can accelerate therapy adoption and increase utilization of Novocure’s TTFields platform. The decision also supports the company’s strategy to expand its presence in international oncology markets while building recurring device-based treatment revenues.
NVCR currently has a market capitalization of $1.48 billion.
Image Source: Zacks Investment Research
More on the News
Optune Lua is a wearable and portable medical device designed to deliver Tumor Treating Fields (TTFields), a therapy that uses alternating electric fields to disrupt the division of cancer cells. These electric fields are administered through non-invasive arrays worn on the patient’s body. By exerting physical forces on electrically charged components inside dividing cancer cells, TTFields interfere with the cell division process, leading to cancer cell death.
The therapy is designed to selectively target cancer cells while minimizing effects on healthy cells. This is due to the biological differences between healthy and malignant cells, including their rate of division, morphology and electrical properties.
Eligible patients will be able to receive Optune Lua therapy at qualified healthcare centers across Japan. The reimbursement coverage is expected to improve patient access to this treatment option, particularly for individuals with advanced or recurrent NSCLC who have limited therapeutic alternatives.
Lung cancer remains the leading cause of cancer-related deaths worldwide. Among its subtypes, NSCLC accounts for around 85% of all lung cancer cases. In Japan alone, around 100,000 patients are diagnosed with NSCLC each year, highlighting the substantial burden of the disease.
Beyond lung cancer, TTFields therapy has demonstrated broad potential across multiple solid tumors. Preclinical studies suggest that combining TTFields with chemotherapy, radiotherapy, immune checkpoint inhibitors or targeted therapies may enhance treatment effects. As a result, the technology offers promising versatility in addressing complex cancer treatment challenges across a range of tumor types.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the metastatic non-small cell lung cancer market is valued at $20.45 billion in 2026 and is expected to witness a CAGR of 10.5% through 2035.
Factors like the global lung cancer incidence and late-stage diagnosis, and advances in targeted therapies, immunotherapies and precision diagnostics are improving survival outcomes and accelerating market growth.
Other News
In February, Novocure received the FDA approval for the Optune Pax for use in adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
Additionally, British Columbia Cancer announced reimbursement coverage for NVCR’s Optune Gio for the treatment of adults newly diagnosed with glioblastoma.
In January, Novocure announced that public health insurers in Czechia have provided reimbursement coverage for Optune Gio for the treatment of adult patients newly diagnosed with glioblastoma.
In December 2025, Novocure submitted the final module of its premarket approval application to the FDA, seeking authorization for its Tumor Treating Fields therapy for the treatment of brain metastases arising from non-small cell lung cancer.
Some top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
Key Takeaways
Novocure (NVCR - Free Report) recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program.
In Japan, Optune Lua is indicated for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable, advanced or recurrent Non???Small Cell Lung Cancer (NSCLC) who have experienced disease progression following platinum-based chemotherapy.
Per management, lung cancer continues to be a major contributor to cancer-related mortality in Japan, underscoring the pressing need for broader access to approved treatment options. The decision by Japan’s Ministry of Health, Labour and Welfare to include Optune Lua under the country’s National Health Insurance reimbursement framework enables patients with advanced Non-Small Cell Lung Cancer to access Optune Lua as an additional therapeutic option.
Likely Trend of NVCR Stock Following the News
Shares of NVCR have lost 3.5% since the announcement on March 2. Over the past six months, shares of the company gained 3% compared with the industry’s 15.5% growth and the S&P 500’s 4.5% rise.
In the long run, the reimbursement approval for Optune Lua in Japan is expected to strengthen the growth prospects of Novocure by expanding patient access through the country’s National Health Insurance. Coverage in Japan, one of the world’s largest healthcare markets, could support increased adoption of the therapy among patients with NSCLC. National insurance coverage reduces financial barriers for patients and healthcare providers, which can accelerate therapy adoption and increase utilization of Novocure’s TTFields platform. The decision also supports the company’s strategy to expand its presence in international oncology markets while building recurring device-based treatment revenues.
NVCR currently has a market capitalization of $1.48 billion.
Image Source: Zacks Investment Research
More on the News
Optune Lua is a wearable and portable medical device designed to deliver Tumor Treating Fields (TTFields), a therapy that uses alternating electric fields to disrupt the division of cancer cells. These electric fields are administered through non-invasive arrays worn on the patient’s body. By exerting physical forces on electrically charged components inside dividing cancer cells, TTFields interfere with the cell division process, leading to cancer cell death.
The therapy is designed to selectively target cancer cells while minimizing effects on healthy cells. This is due to the biological differences between healthy and malignant cells, including their rate of division, morphology and electrical properties.
Eligible patients will be able to receive Optune Lua therapy at qualified healthcare centers across Japan. The reimbursement coverage is expected to improve patient access to this treatment option, particularly for individuals with advanced or recurrent NSCLC who have limited therapeutic alternatives.
Lung cancer remains the leading cause of cancer-related deaths worldwide. Among its subtypes, NSCLC accounts for around 85% of all lung cancer cases. In Japan alone, around 100,000 patients are diagnosed with NSCLC each year, highlighting the substantial burden of the disease.
Beyond lung cancer, TTFields therapy has demonstrated broad potential across multiple solid tumors. Preclinical studies suggest that combining TTFields with chemotherapy, radiotherapy, immune checkpoint inhibitors or targeted therapies may enhance treatment effects. As a result, the technology offers promising versatility in addressing complex cancer treatment challenges across a range of tumor types.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the metastatic non-small cell lung cancer market is valued at $20.45 billion in 2026 and is expected to witness a CAGR of 10.5% through 2035.
Factors like the global lung cancer incidence and late-stage diagnosis, and advances in targeted therapies, immunotherapies and precision diagnostics are improving survival outcomes and accelerating market growth.
Other News
In February, Novocure received the FDA approval for the Optune Pax for use in adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
Additionally, British Columbia Cancer announced reimbursement coverage for NVCR’s Optune Gio for the treatment of adults newly diagnosed with glioblastoma.
In January, Novocure announced that public health insurers in Czechia have provided reimbursement coverage for Optune Gio for the treatment of adult patients newly diagnosed with glioblastoma.
In December 2025, Novocure submitted the final module of its premarket approval application to the FDA, seeking authorization for its Tumor Treating Fields therapy for the treatment of brain metastases arising from non-small cell lung cancer.
NovoCure Limited Price
NovoCure Limited price | NovoCure Limited Quote
NVCR’s Zacks Rank & Key Picks
Currently, NVCR carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.